In particular, BCR-ABL peptide vaccination not only stimulated specific tumor-specific immune responses in patients with CML, it also allowed a reduction in the imatinib dose given and the benefit persistence of a CML complete molecular response [32]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.